Integrating Advances from Stage IV Non-Small Cell Lung Cancer (NSCLC) into the Curative Setting
Cancer care and its treatment is a fast-evolving environment. The advances in research have led to improvements in overall survival. This knowledge can lead to individualized and targeted treatments that lead to this improved survival, however, staying up to date with these advancements is a challenge in this fast-changing landscape. Providers in the community setting are typically seeing many different cancer types, which is hard to stay current on all. As it is a challenge for oncology providers to stay up to date, this activity seeks to bridge the gap by sharing these recent advances, which can lead to better patient outcomes.
Target Audience
AccessHope physicians, nurses, and patient navigators.
Learning Objectives
- Review current, established models for care in the curative setting of resectable and locally advanced unresectable Non-Small Cell Lung Cancer (NSCLC).
- Summarize recent advances that have introduced new management approaches in these settings.
- Identify current leading open questions and controversies in stage I-II NSCLC, along with some of the pivotal ongoing trials seeking to address these topics.
- Discuss possible barriers and biases which may impact patient care (i.e., race, ethnicity, language, gender identity/orientation, age, socioeconomic status, attitudes, feelings, or other characteristics).
Virtual Meeting- Zoom
H. Jack West, MD Associate Professor, Department of Medical Oncology, City of Hope; Medical Director, AccessHope
Dr. West has indicated that he is a Consultant for Amgen, AstraZeneca, Genentech/Roche, Merck, Mirati, Regeneron, and Takeda; and is On the Speakers Bureau for Amgen, AstraZeneca, Merck, and Mirati.
ACCREDITATION STATEMENT: City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CREDIT DESIGNATION: City of Hope designates this live webinar for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The following credit type(s) are being offered for this course:
• AMA PRA Category 1 Credit™ 1.0
The following may apply AMA PRA Category 1 Credit™ for license renewal:
Registered Nurses: Nurses may report up to 1.0 credit hours toward the continuing education requirements for license renewal by their state Board of Registered Nurses (BRN). AMA PRA Category 1 Credit™ may be noted on the license renewal application in lieu of a BRN provider number.
Physician Assistants: The National Commission on Certification of Physicians Assistants states that AMA PRA Category 1 Credit™ accredited courses are acceptable for CME requirements for recertification.
Available Credit
- 1.00 AMA PRA Category 1 Credit™City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
City of Hope designates this Integrating Advances from Stage IV Non-Small Cell Lung Cancer (NSCLC) into the Curative Setting for a maximum of 1.00 AMA PRA Category 1 Credit™ requirements. Physicians should claim only the credit commensurate with the extent of their participation in the activity. - 1.00 Attendance